Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâ€™s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Employees

Sector

Biotechnology & Medical Research

More about the company

09-24	Heidelberg Pharma AG Presents New Clinical Data For Lead ATAC Candidate Pamlectabart Tismanitin At IMS Annual Meeting 2026	CI
09-07	Heidelberg Pharma AG Presents New Clinical Data On Lead ATAC Candidate Pamlectabart Tismanitin At International Myeloma Society Annual Meeting	CI

Market Cap	121M 138M 114M 104M 194M 13.18B 196M 1.36B 528M 6.74B 516M 505M 21.65B	P/E 2026 *	-4.97x	P/E 2027 *	-5.14x
Enterprise Value	113M 129M 107M 97.07M 182M 12.32B 183M 1.27B 494M 6.29B 483M 472M 20.22B	EV / Sales 2026 *	11.3x	EV / Sales 2027 *	7.96x
Free-Float	21%	Yield 2026 *	-	Yield 2027 *	-

09-24	Heidelberg Pharma AG Presents New Clinical Data For Lead ATAC Candidate Pamlectabart Tismanitin At IMS Annual Meeting 2026	CI
09-07	Heidelberg Pharma AG Presents New Clinical Data On Lead ATAC Candidate Pamlectabart Tismanitin At International Myeloma Society Annual Meeting	CI
08-28	Heidelberg Pharma And Huadong Medicine Co., Ltd. Sign Additional Collaboration Agreement To Jointly Develop New Antibody Drug Conjugates	CI
08-27	Heidelberg Pharma Wins Chinese Nod to Start Myeloma Combination Therapy Trial	MT
08-26	Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China	CI
07-15	Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2026	CI
06-23	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI
04-29	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2026	CI
04-17	Heidelberg Pharma AG Announces Chief Financial Officer Changes	CI
04-09	Heidelberg Pharma Sets Dose for Mid-stage Trial of Multiple Myeloma Drug Candidate	MT
04-09	Heidelberg Pharma AG Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101	CI
04-04	Heidelberg Pharma AG Presents Data from Its ADC Technology Platform At AACR Annual Meeting	CI
03-31	Heidelberg Pharma AG, 2025 Earnings Call, Mar 26, 2026

09-24	Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026	EQ
09-07	Heidelberg Pharma to Present New Clinical Data on Lead ATAC Candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026	EQ
08-31	Heidelberg Pharma and Huadong Medicine Sign Further Cooperation Agreement for the Joint Development of New Antibody-Drug Conjugates	AQ
08-28	Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates	EQ
08-28	Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates	EQ

09-24	Heidelberg Pharma präsentiert neue klinische Daten zum führenden ATAC-Kandidaten pamlectabart tismanitin auf der IMS-Jahrestagung 2026
09-07	Heidelberg Pharma präsentiert neue klinische Daten ihres führenden ATAC-Kandidaten pamlectabart tismanitin auf der Jahrestagung 2026 der International Myeloma Society
08-28	Heidelberg Pharma und Huadong Medicine unterzeichnen weitere Kooperationsvereinbarung zur gemeinsamen Entwicklung neuer Antikörper-Wirkstoff-Konjugate
08-28	Heidelberg Pharma und Huadong Medicine unterzeichnen weitere Kooperationsvereinbarung zur gemeinsamen Entwicklung neuer Antikörper-Wirkstoff-Konjugate
08-26	Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie in China

Wilex AG Stock Deutsche Boerse AG

Stocks

DE0006614720

Biotechnology & Medical Research

Valuation: Wilex AG

Latest news: Wilex AG

Last Transcript: Wilex AG

Analysts' recommendations: Wilex AG

Press Releases: Wilex AG

News in other languages: Wilex AG

Managers and Directors: Wilex AG

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Dong Zhou Liu CEO	Chief Executive Officer	-	2025-11-23
Peter Willinger DFI	Director of Finance/CFO	-	2026-04-30
András Strassz CTO	Chief Tech/Sci/R&D Officer	-	2021-02-28

Director	Title	Age	Since
Georg F. Baur CHM	Chairman	76	2000-12-13
Birgit Kudlek BRD	Director/Board Member	59	2012-05-24
Mathias Hothum BRD	Director/Board Member	58	2015-07-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-3.30%	+1.50%	+57.79%	+99.14%	72.26B
ARGENX SE	+1.25%	-3.01%	+37.83%	+87.66%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+2.12%	+5.26%	+35.69%	+23.40%	27.73B
INSMED INCORPORATED	-3.06%	-1.81%	-14.01%	+357.24%	25.73B
BIONTECH SE	-0.75%	+2.56%	+0.45%	-3.28%	24.75B
GENMAB A/S	+0.40%	+0.75%	+23.72%	-11.33%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+150.24%	+326.97%	15.06B
EXELIXIS, INC.	+0.36%	-0.34%	+48.98%	+167.40%	14.41B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.21%	+1.17%	-3.95%	+512.06%	14.23B
Average	-0.50%	+0.44%	+37.41%	+173.25%	30.57B
Weighted average by Cap.	-0.77%	+0.31%	+38.16%	+132.99%

	2026 *	2027 *
Net sales	10M 11.4M 9.44M 8.61M 16.11M 1.09B 16.23M 113M 43.77M 558M 42.79M 41.86M 1.79B	13M 14.81M 12.28M 11.19M 20.95M 1.42B 21.09M 147M 56.91M 725M 55.62M 54.42M 2.33B
Net income	-24.3M -27.69M -22.95M -20.91M -39.15M -2.65B -39.43M -275M -106M -1.36B -104M -102M -4.36B	-23.5M -26.78M -22.19M -20.23M -37.86M -2.57B -38.13M -266M -103M -1.31B -101M -98.38M -4.21B
Net Debt	-7.93M -9.04M -7.49M -6.82M -12.77M -866M -12.87M -89.61M -34.71M -442M -33.92M -33.19M -1.42B	-17.24M -19.64M -16.28M -14.83M -27.77M -1.88B -27.97M -195M -75.45M -962M -73.74M -72.15M -3.09B

End-of-day quote Deutsche Boerse AG
- ^EUR	-